Del Roc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa

The council leader helped launched this year’s Carreta Solidaria campaign, during which, 400 kilos of non-perishable food was collected for local families in danger of so

The south of Spain is popular with tourists from all over the world; year-round sunshine, spectacular beaches, vibrant cities and beautiful scenery make the perfect combi

The EU’s clean-energy targets require training up a new workforce.

Forced sterilisation is legal in much of the European Union. It is against the law in only nine countries despite contravening the Istanbul Convention.